RO5313534 / Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RO5313534 / Roche
NCT00604760: Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Unknown status
2a
160
US
MEM 3454, Placebo for MEM 3454
Memory Pharmaceuticals
Cognitive Impairment Associated With Schizophrenia
02/09
 
NCT00454870: Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

Completed
2
80
US
MEM 3454
Memory Pharmaceuticals
Alzheimer's Disease
10/07
10/07
P50, NCT00725855: A Single-Center, Double-Blind (DB) Study of MEM 3454 on Sensory Gating and Mismatch Negativity in Schizophrenia Patients

Unknown status
2
12
US
MEM 3454, Placebo for MEM 3454
Memory Pharmaceuticals, Hoffmann-La Roche
Schizophrenia
03/09
04/09
NCT00884507 / 2008-004012-13: A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

Completed
2
389
US, Canada, Europe, RoW
Placebo, RO5313534
Hoffmann-La Roche
Alzheimer's Disease
11/10
11/10

Download Options